Sanofi keeps nip­ping at J&J's heels as Sar­clisa notch­es new FDA ap­proval in mul­ti­ple myelo­ma

The mul­ti­ple myelo­ma ri­val­ry be­tween Sanofi and J&J con­tin­ued Wednes­day evening, with the French drug­mak­er’s Sar­clisa tak­ing home a new ap­proval in the in­di­ca­tion.

US reg­u­la­tors OK’d the drug in com­bi­na­tion with Am­gen’s Kypro­lis and the steroid dex­am­etha­sone for adults with re­lapsed or re­frac­to­ry mul­ti­ple myelo­ma who have re­ceived be­tween one and three pre­vi­ous lines of treat­ment. It’s the sec­ond ap­proval for Sar­clisa, hav­ing pre­vi­ous­ly won a green light in March 2020 as a third-line treat­ment for the dis­ease.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN